Follow the 애드바이오텍 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 애드바이오텍 has recorded 56 reports. Market capitalisation: €40.6bn. The latest transaction was filed on 4 June 2026 (Other). Among the most active insiders: SBI인베스트먼트. All data is openly available.
56
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
n/a
33 ops.
Sell Volume
13Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,200 of 28,065 companies
22.1
score / 100
Value
22
Quality
23
FCF yld-4.2%
Earn yld-8.1%
EV/EBITDA·
ROE-80%
Gross mgn40%
Net mgn-26%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
애드바이오텍 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for patient health and well-being.